Nicole Sweeny is CCO at KalVista Pharmaceuticals, Inc. (KALV). They have made 7 open-market trades across 1 company since 2025, most recently 2026-05-26.
CIK 0001827505
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PRAX | 38,619 | $9.4M |
| KALV | 59,291 | $1.6M |
| Total | $11.0M |
Shares reported on the most recent Form 4, priced at the 2026-05-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2026-05-26 | 2026-05-27 | $26.78 | $40K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-05-22 | 2026-05-26 | $26.78 | $50K | +0.7% | N/A | N/A |
| KALV | SELL | 2026-04-17 | 2026-04-20 | $20.22 | $38K | +26.2% | +27.0% | N/A |
| KALV | SELL | 2026-02-23 | 2026-02-24 | $15.57 | $62K | +2.8% | +20.0% | +69.8% |
| KALV | SELL | 2025-11-24 | 2025-12-04 | $13.45 | $103K | -3.5% | -5.0% | -0.7% |
| KALV | SELL | 2025-08-25 | 2025-08-26 | $13.42 | $20K | +21.2% | -8.2% | +1.4% |
| KALV | SELL | 2025-08-22 | 2025-08-25 | $13.22 | $25K | +22.8% | +0.2% | +3.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.